

## **REMARKS**

### **I. Restriction Requirement**

The Office Action required election of a Group of claims from among Groups I-IV and election of a species of single compound where the base functional group is selected from (a) to (h) and where the variables are the R groups, X, and m values. In response Applicants elect, without traverse, the claims of Group II, and the species of single compound S36, as encompassed by chemical formula (g).

The Office Action also required identification of the claims encompassing the elected species, including any subsequently added claims. The claims that encompass the elected species S36 are claims 13, 15, 17, 18, 25, 26, 29, 30, 33, 34, and 35 and new claims 43-46, i.e. all of the currently pending claims as presented herein.

### **II. Amendment to the Claims**

Claims 1-42 were previously pending. By this paper, claims 1-12, 14, 16, 19-24, 27-28, 31-32, and 36-42 are canceled, claims 13, 17, 18, 25, 29, 30, 33, and 34 are amended, and new claims 43-46 are added. No new matter is added by this amendment. Support for the amended and new claims can be found in the specification as filed. For example, support for methods of increasing binding of FKBP12.6 to RyR2 in a subject can be found in paragraph 104 of the application as filed, support for methods of treatment of cardiac conditions in general can be found at paragraphs 106, 245, and 255 of the application as filed, support for the cardiac conditions recited in the amended claims can be found in paragraphs 106-110, 245, and 255 of the application as filed, support for the effective amounts and doses recited in the amended claims can be found in paragraphs 257-259, 269-270, and 341 of the application as filed, and support for the compounds recited in new claims 44-46 can be found in paragraphs 182-191, 242, and 244 of the application as filed (paragraph numbers as in published application 2005/0215540).

New claim 43 depends from a previously pending claim, and accordingly encompasses the elected species S36. New claims 44-46 are directed to the compound S36 and/or to compounds of formula (g) which encompasses S36. Accordingly, Applicants submit there would no additional or undue burden associated with conducting a search and examination of

new claims 43-36 because such a search and examination would necessarily be co-extensive with the search and examination required for the previously pending claims of Group II and the elected species S36, as encompassed by formula (g).

Respectfully submitted,

/Jane M. Love, Ph.D./  
Jane M. Love, Ph.D.  
Reg. No. 42,812

Date: November 1, 2007

Wilmer Cutler Pickering Hale and Dorr, LLP  
399 Park Avenue  
New York, New York 10022  
Tel: (212) 937-7233  
Fax: (212) 230-8888  
jane.love@wilmerhale.com